These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11759055)

  • 1. Specific but variable expression of h-caldesmon in leiomyosarcomas: an immunohistochemical reassessment of a novel myogenic marker.
    Hisaoka M; Wei-Qi S; Jian W; Morio T; Hashimoto H
    Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):302-8. PubMed ID: 11759055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma.
    Sakamoto A; Oda Y; Yamamoto H; Oshiro Y; Miyajima K; Itakura E; Tamiya S; Honda Y; Ishihara A; Iwamoto Y; Tsuneyoshi M
    Virchows Arch; 2002 Apr; 440(4):404-9. PubMed ID: 11956822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue.
    Perez-Montiel MD; Plaza JA; Dominguez-Malagon H; Suster S
    Am J Dermatopathol; 2006 Apr; 28(2):105-11. PubMed ID: 16625070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunohistochemical differentiation of leiomyocellular tumors and tumors with myogenic differentiation].
    Povýsil C; Ciprová V; Dundr P; Horáková M
    Cesk Patol; 2003 Apr; 39(2):64-8. PubMed ID: 12874903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is anti-h-caldesmon useful for distinguishing smooth muscle and myofibroblastic tumors? An immunohistochemical study.
    Ceballos KM; Nielsen GP; Selig MK; O'Connell JX
    Am J Clin Pathol; 2000 Nov; 114(5):746-53. PubMed ID: 11068549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calponin and h-caldesmon in soft tissue tumors: consistent h-caldesmon immunoreactivity in gastrointestinal stromal tumors indicates traits of smooth muscle differentiation.
    Miettinen MM; Sarlomo-Rikala M; Kovatich AJ; Lasota J
    Mod Pathol; 1999 Aug; 12(8):756-62. PubMed ID: 10463476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors.
    Robin YM; Penel N; Pérot G; Neuville A; Vélasco V; Ranchère-Vince D; Terrier P; Coindre JM
    Mod Pathol; 2013 Apr; 26(4):502-10. PubMed ID: 23174934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors.
    Nucci MR; O'Connell JT; Huettner PC; Cviko A; Sun D; Quade BJ
    Am J Surg Pathol; 2001 Apr; 25(4):455-63. PubMed ID: 11257619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies.
    Oliva E; Young RH; Amin MB; Clement PB
    Am J Surg Pathol; 2002 Apr; 26(4):403-12. PubMed ID: 11914617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudosarcomatous myofibroblastic tumor and myosarcoma of the urogenital tract.
    Watanabe K; Baba K; Saito A; Hoshi N; Suzuki T
    Arch Pathol Lab Med; 2001 Aug; 125(8):1070-3. PubMed ID: 11473460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H-caldesmon expression in myofibroblastoma of the breast: evidence supporting the distinction from leiomyoma.
    Magro G; Gurrera A; Bisceglia M
    Histopathology; 2003 Mar; 42(3):233-8. PubMed ID: 12605642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma.
    Loddenkemper C; Mechsner S; Foss HD; Dallenbach FE; Anagnostopoulos I; Ebert AD; Stein H
    Am J Surg Pathol; 2003 Nov; 27(11):1458-62. PubMed ID: 14576480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. h-Caldesmon in leiomyosarcoma and tumors with smooth muscle cell-like differentiation: its specific expression in the smooth muscle cell tumor.
    Watanabe K; Kusakabe T; Hoshi N; Saito A; Suzuki T
    Hum Pathol; 1999 Apr; 30(4):392-6. PubMed ID: 10208459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. h-Caldesmon as a specific marker of smooth muscle cell differentiation in some soft tissue tumors of the skin.
    D'Addario SF; Morgan M; Talley L; Smoller BR
    J Cutan Pathol; 2002 Aug; 29(7):426-9. PubMed ID: 12139638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. h-Caldesmon as a specific marker for smooth muscle tumors. Comparison with other smooth muscle markers in bone tumors.
    Watanabe K; Tajino T; Sekiguchi M; Suzuki T
    Am J Clin Pathol; 2000 May; 113(5):663-8. PubMed ID: 10800398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tale of two clones: Caldesmon staining in the differentiation of cutaneous spindle cell neoplasms.
    Beck EM; Bauman TM; Rosman IS
    J Cutan Pathol; 2018 Aug; 45(8):581-587. PubMed ID: 29687929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular leiomyosarcoma: Clinicopathology and immunohistochemistry with special reference to a unique smooth muscle phenotype.
    Matsuyama A; Hisaoka M; Hashimoto H
    Pathol Int; 2010 Mar; 60(3):212-6. PubMed ID: 20403047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of smooth muscle markers in so called malignant fibrous histiocytomas.
    Hasegawa T; Hasegawa F; Hirose T; Sano T; Matsuno Y
    J Clin Pathol; 2003 Sep; 56(9):666-71. PubMed ID: 12944549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value.
    Demicco EG; Boland GM; Brewer Savannah KJ; Lusby K; Young ED; Ingram D; Watson KL; Bailey M; Guo X; Hornick JL; van de Rijn M; Wang WL; Torres KE; Lev D; Lazar AJ
    Histopathology; 2015 Apr; 66(5):627-38. PubMed ID: 24889065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus.
    de Leval L; Waltregny D; Boniver J; Young RH; Castronovo V; Oliva E
    Am J Surg Pathol; 2006 Mar; 30(3):319-27. PubMed ID: 16538051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.